HS
CABA icon

HighVista Strategies’s Cabaletta Bio CABA Stock Holding History

HighVista Strategies’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,208
Closed -$166K – 147
2024
Q2 		$166K Hold
22,208
– – 0.06% 137
2024
Q1 		$379K Buy
+22,208
New +$477K 0.14% 129

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

HighVista Strategies's CABA Position: Q3 2024 in Review

HighVista Strategies sold out of Cabaletta Bio (CABA) in Q3 2024, closing a stake of 22,208 shares — an estimated $166K sold.

HighVista Strategies first reported a position in CABA in Q1 2024 and held it in 2 quarters. The position peaked at $379K in Q1 2024. 120 funds tracked by Wall St. Rank hold CABA as of Q3 2024.

  • HighVista Strategies reported no remaining Cabaletta Bio position as of Q3 2024 after selling out during the quarter.
  • HighVista Strategies sold 22,208 Cabaletta Bio shares in Q3 2024, an estimated $166K.
  • HighVista Strategies first reported a position in Cabaletta Bio in Q1 2024 and held it in 2 quarters.
  • HighVista Strategies's Cabaletta Bio position peaked at $379K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2024.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.